Flputnam Investment Management Co. Sells 5,399 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Flputnam Investment Management Co. reduced its stake in Thermo Fisher Scientific by 13.2%, selling 5,399 shares and now holding 35,655 shares valued at $17.74 million.
• Thermo Fisher reported earnings per share of $5.36 for the most recent quarter, outperforming the consensus estimate, with a revenue of $10.86 billion, a 2.9% year-over-year increase.
• The company declared a quarterly dividend of $0.43 with an annualized yield of 0.3%, indicating a low payout ratio of 9.95%.

Flputnam Investment Management Co. trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,655 shares of the medical research company's stock after selling 5,399 shares during the period. Flputnam Investment Management Co.'s holdings in Thermo Fisher Scientific were worth $17,742,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMO. Mondrian Investment Partners LTD lifted its position in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock valued at $106,738,000 after acquiring an additional 127,357 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares during the last quarter. Deutsche Bank AG grew its stake in Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after buying an additional 114,277 shares in the last quarter. Cetera Trust Company N.A grew its stake in Thermo Fisher Scientific by 3.3% in the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock valued at $2,312,000 after buying an additional 150 shares in the last quarter. Finally, Philip James Wealth Mangement LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $268,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.7%

Shares of NYSE TMO opened at $493.05 on Friday. The firm's 50 day moving average price is $452.50 and its 200-day moving average price is $454.32. The company has a market cap of $186.18 billion, a PE ratio of 28.52, a P/E/G ratio of 2.63 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,896 shares of company stock valued at $13,603,438. Corporate insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on TMO shares. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.